Inhibikase Therapeutics Inc

NASDAQ:IKT   3:59:50 PM EDT
2.18
+0.09 (+4.31%)
Earnings Announcements

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results And Highlights Recent Period Activity

Published: 08/16/2021 21:03 GMT
Inhibikase Therapeutics Inc (IKT) - Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity.
Q2 Loss per Share $0.22.
Qtrly Revenue $1.4 Million.
Revenue is expected to be $0.2 Million
Adjusted EPS is expected to be -$0.14

Next Quarter Revenue Guidance is expected to be $0.2 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.